Methylmalonic acid (MMA), a serum oncometabolite, increased the expression of inhibin βA (INHBA) by the neuroendocrine-specific transcription factor, FOXA2 to induce MITF-mediated EMT during the progression of pancreatic neuroendocrine neoplasms (PanNENs), providing an actionable therapeutic vulnerability to metabolic therapy in PanNENs. The gene discussed is MITF; the disease is pancreatic neuroendocrine neoplasm.